Загрузка...
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
SIMPLE SUMMARY: Immunotherapy has made a breakthrough in the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma in the second line setting with anti-PD-1/PD-L1 immune checkpoint inhibitors. Furthermore, the KEYNOTE-048 study has established a new standard of...
Сохранить в:
| Опубликовано в: : | Cancers (Basel) |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8197177/ https://ncbi.nlm.nih.gov/pubmed/34073885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112573 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|